DE68903165T2 - Rns des genoms des non-a, non-b-hepatitisvirus und antigenisches virales protein. - Google Patents
Rns des genoms des non-a, non-b-hepatitisvirus und antigenisches virales protein.Info
- Publication number
- DE68903165T2 DE68903165T2 DE8989313362T DE68903165T DE68903165T2 DE 68903165 T2 DE68903165 T2 DE 68903165T2 DE 8989313362 T DE8989313362 T DE 8989313362T DE 68903165 T DE68903165 T DE 68903165T DE 68903165 T2 DE68903165 T2 DE 68903165T2
- Authority
- DE
- Germany
- Prior art keywords
- hepatitis
- infection
- cdna
- nanb
- hepatitis virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 35
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 35
- 241000700605 Viruses Species 0.000 title claims abstract description 23
- 230000000890 antigenic effect Effects 0.000 title claims description 7
- 108010067390 Viral Proteins Proteins 0.000 title 1
- 239000002299 complementary DNA Substances 0.000 claims abstract description 21
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 238000010804 cDNA synthesis Methods 0.000 claims description 4
- 108020004635 Complementary DNA Proteins 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 abstract description 8
- 108091007433 antigens Proteins 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 description 36
- 241000282577 Pan troglodytes Species 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 239000012528 membrane Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 241000711549 Hepacivirus C Species 0.000 description 5
- 241000282579 Pan Species 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 239000013614 RNA sample Substances 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000012677 causal agent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 1
- -1 DAB Substances 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63322547A JPH02167081A (ja) | 1988-12-21 | 1988-12-21 | 非Ａ非Ｂ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡおよびウイルス抗原蛋白質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE68903165D1 DE68903165D1 (de) | 1992-11-12 |
| DE68903165T2 true DE68903165T2 (de) | 1993-03-11 |
Family
ID=18144889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8989313362T Expired - Fee Related DE68903165T2 (de) | 1988-12-21 | 1989-12-20 | Rns des genoms des non-a, non-b-hepatitisvirus und antigenisches virales protein. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5077193A (enExample) |
| EP (1) | EP0377303B1 (enExample) |
| JP (1) | JPH02167081A (enExample) |
| AT (1) | ATE81357T1 (enExample) |
| CA (1) | CA2005950C (enExample) |
| DE (1) | DE68903165T2 (enExample) |
| DK (1) | DK648689A (enExample) |
| ES (1) | ES2045475T3 (enExample) |
| GR (1) | GR3006171T3 (enExample) |
| IE (1) | IE63306B1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698390A (en) * | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
| US5714596A (en) * | 1987-11-18 | 1998-02-03 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
| US6861212B1 (en) | 1987-11-18 | 2005-03-01 | Chiron Corporation | NANBV diagnostics and vaccines |
| US5712088A (en) * | 1987-11-18 | 1998-01-27 | Chiron Corporation | Methods for detecting Hepatitis C virus using polynucleotides specific for same |
| US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
| US6171782B1 (en) | 1987-11-18 | 2001-01-09 | Chiron Corporation | Antibody compositions to HCV and uses thereof |
| US5789559A (en) * | 1988-06-17 | 1998-08-04 | Genelabs Technologies, Inc. | DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent |
| US5824649A (en) * | 1988-06-17 | 1998-10-20 | Genelabs Technologies, Inc. | DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof |
| US5191064A (en) * | 1988-09-30 | 1993-03-02 | The Research Foundation For Microbial Diseases (Osaka University) | Non-a, non-b hepatitis virus antigen peptide |
| US6027729A (en) * | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
| US5372928A (en) * | 1989-09-15 | 1994-12-13 | Chiron Corporation | Hepatitis C virus isolates |
| CA2032381C (en) | 1989-12-18 | 2006-02-21 | Peter E. Highfield | Viral agent |
| US7166287B1 (en) | 1989-12-18 | 2007-01-23 | Glaxo Wellcome Inc. | Viral agent |
| US5747339A (en) * | 1990-06-25 | 1998-05-05 | Research Foundation For Microbial Diseases Of Osaka | Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide |
| WO1992003458A1 (en) * | 1990-08-25 | 1992-03-05 | New York Blood Center | Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines |
| US7863008B2 (en) | 1990-08-25 | 2011-01-04 | Bioprocess Pty Ltd. | Method for detecting NANBV associated seroconversion |
| US5574132A (en) * | 1991-04-05 | 1996-11-12 | Biochem Immunosystems Inc. | Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV) |
| EP0516270A3 (en) * | 1991-04-10 | 1993-06-23 | Immuno Japan Inc. | Non-a, non-b hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides |
| WO1993006126A1 (en) * | 1991-09-13 | 1993-04-01 | Chiron Corporation | Immunoreactive hepatitis c virus polypeptide compositions |
| WO1994018217A1 (en) * | 1993-02-03 | 1994-08-18 | Abbott Laboratories | Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use |
| US5859230A (en) * | 1992-07-30 | 1999-01-12 | Genelabs Technologies, Inc. | Non-A/non-B/non-C/non-D/non-E hepatitis agents and molecular cloning thereof |
| US7258977B1 (en) | 1992-11-27 | 2007-08-21 | Innogenetics N.V. | Process for typing of HCV isolates |
| WO1994012670A2 (en) | 1992-11-27 | 1994-06-09 | N.V. Innogenetics S.A. | Process for typing of hcv isolates |
| US5824507A (en) * | 1994-05-20 | 1998-10-20 | Genelabs Technologies, Inc. | Hepatitis G virus and molecular cloning thereof |
| US5874563A (en) * | 1994-05-20 | 1999-02-23 | Genelabs Technologies, Inc. | Hepatitis G virus and molecular cloning thereof |
| US7235394B1 (en) | 1995-08-29 | 2007-06-26 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| US6127116A (en) * | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| US7338759B1 (en) | 1997-03-04 | 2008-03-04 | Washington University | HCV variants |
| US7049428B1 (en) | 1998-03-04 | 2006-05-23 | Washington University | HCV variants |
| US6586584B2 (en) | 2001-01-29 | 2003-07-01 | Becton, Dickinson And Company | Sequences and methods for detection of Hepatitis C virus |
| US7196183B2 (en) * | 2001-08-31 | 2007-03-27 | Innogenetics N.V. | Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent |
| ES2596753T3 (es) * | 2003-08-29 | 2017-01-11 | Fujirebio Europe N.V. | Nuevo clado del virus de la hepatitis C y secuencias prototipo del mismo |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3744242A1 (de) * | 1987-02-20 | 1989-07-06 | Seelig Renate | Virusantigen, verfahren zu seiner gewinnung und anwendung in diagnose und therapie (impfstoff) |
| IE62868B1 (en) * | 1987-11-18 | 1995-03-08 | Chiron Corp | Hepatitis C virus |
| IL91371A0 (en) * | 1988-08-24 | 1990-04-29 | Us Commerce | Clones or vectors bearing dna sequences of non-a and non-b hepatitis and a method for detecting these materials in blood |
-
1988
- 1988-12-21 JP JP63322547A patent/JPH02167081A/ja active Pending
-
1989
- 1989-12-19 DK DK648689A patent/DK648689A/da not_active Application Discontinuation
- 1989-12-19 CA CA002005950A patent/CA2005950C/en not_active Expired - Fee Related
- 1989-12-19 IE IE408389A patent/IE63306B1/en not_active IP Right Cessation
- 1989-12-20 DE DE8989313362T patent/DE68903165T2/de not_active Expired - Fee Related
- 1989-12-20 ES ES89313362T patent/ES2045475T3/es not_active Expired - Lifetime
- 1989-12-20 AT AT89313362T patent/ATE81357T1/de not_active IP Right Cessation
- 1989-12-20 EP EP89313362A patent/EP0377303B1/en not_active Expired - Lifetime
-
1990
- 1990-06-19 US US07/540,604 patent/US5077193A/en not_active Expired - Fee Related
-
1992
- 1992-11-05 GR GR920402492T patent/GR3006171T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2005950C (en) | 1996-06-11 |
| ATE81357T1 (de) | 1992-10-15 |
| EP0377303A1 (en) | 1990-07-11 |
| ES2045475T3 (es) | 1994-01-16 |
| DK648689A (da) | 1990-06-22 |
| IE63306B1 (en) | 1995-04-05 |
| CA2005950A1 (en) | 1990-06-21 |
| EP0377303B1 (en) | 1992-10-07 |
| US5077193A (en) | 1991-12-31 |
| DK648689D0 (da) | 1989-12-19 |
| IE894083L (en) | 1990-06-21 |
| JPH02167081A (ja) | 1990-06-27 |
| DE68903165D1 (de) | 1992-11-12 |
| GR3006171T3 (enExample) | 1993-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68903165T2 (de) | Rns des genoms des non-a, non-b-hepatitisvirus und antigenisches virales protein. | |
| DE68928119T2 (de) | Non-A, non-B-Hepatitisvirus-Antigenpeptid | |
| AT400724B (de) | Virales polypeptid | |
| DE69533675T2 (de) | Monoklonaler antikörper gegen rhesus d (d7c2) | |
| DE68929467T2 (de) | HIV-2 Varianten | |
| EP0770679B1 (de) | HCV-spezifische Peptide, Mittel dazu und ihre Verwendung | |
| DE3886363T3 (de) | NANBV-Diagnostika | |
| DE69637264T2 (de) | Virales Material und Multiple-Sklerose assoziierte Nukleotidfragmente mit diagnostischen, prophylaktischen und therapeutischen Verwendungen | |
| DE69434117T3 (de) | Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien | |
| DE60013287T2 (de) | Früherkennung der flaviviren unter verwendung des ns1-glycoproteins | |
| DE3588177T2 (de) | Verfahren zur Feststellung der Anwesenheit eines selbstimmunen Antikörpers | |
| DE19543553A1 (de) | VP-Antigene des JC-Virus | |
| DE69532062T2 (de) | Immuntests von nicht-A, nicht-B Hepatitisvirus-verwandten Antigenen, monoklonale Antikörper und diese synthetisierende Hybridome | |
| DE69433964T2 (de) | Multiple Sclerosis Virus | |
| DE68926658T2 (de) | Diagnostische gene zum nachweis von toxoplasmose | |
| EP0124896B1 (de) | Verfahren zur Gewinnung von Viren bzw. Virusantigenen und deren Anwendung in Diagnose und Therapie (Impfstoff) | |
| DE69224134T2 (de) | Monoklonale Antikörper gegen Hepatitis-C-Virus | |
| US5176994A (en) | Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein | |
| DE69106141T2 (de) | Non-a non-b sequenzen. | |
| EP0564532B1 (de) | Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung | |
| DE69731106T2 (de) | Neue pikcornaviren, impfstoffe und diagnostische kits | |
| DE69121933T2 (de) | Nukleinsäuren, Antigene und Antikörper betreffend Non-A, Non-B Hepatitis und deren Nachweisreagenzien | |
| DE60034243T2 (de) | Rekombinante bifunktionale fusionsproteine zur abtreibung variabler viren | |
| DE69929024T2 (de) | Immunschwächevirus Stamm FIV-141 der Katze und dessen Verwendungen | |
| DE69200512T2 (de) | Mit Antikörper gegen Hepatitis non-A, non-B-Virus immunochemische reaktive Peptide. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |